Acetylation-Dependent Regulation of Skp2 Function
Author(s) -
Hiroyuki Inuzuka,
Daming Gao,
Lydia W.S. Finley,
Wen Yang,
Lixin Wan,
Hidefumi Fukushima,
Y. Rebecca Chin,
Bo Zhai,
Shavali Shaik,
Alan W. Lau,
Zhiwei Wang,
Steven P. Gygi,
Keiko Nakayama,
Julie TeruyaFeldstein,
Alex Toker,
Marcia C. Haigis,
Pier Paolo Pandolfi,
Wenyi Wei
Publication year - 2012
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2012.05.038
Subject(s) - acetylation , biology , microbiology and biotechnology , ubiquitin , carcinogenesis , cytoplasm , skp2 , cancer research , cancer , ubiquitin ligase , genetics , gene
Aberrant Skp2 signaling has been implicated as a driving event in tumorigenesis. Although the underlying molecular mechanisms remain elusive, cytoplasmic Skp2 correlates with more aggressive forms of breast and prostate cancers. Here, we report that Skp2 is acetylated by p300 at K68 and K71, which is a process that can be antagonized by the SIRT3 deacetylase. Inactivation of SIRT3 leads to elevated Skp2 acetylation, which leads to increased Skp2 stability through impairment of the Cdh1-mediated proteolysis pathway. As a result, Skp2 oncogenic function is increased, whereby cells expressing an acetylation-mimetic mutant display enhanced cellular proliferation and tumorigenesis in vivo. Moreover, acetylation of Skp2 in the nuclear localization signal (NLS) promotes its cytoplasmic retention, and cytoplasmic Skp2 enhances cellular migration through ubiquitination and destruction of E-cadherin. Thus, our study identifies an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provides insight into how cytoplasmic Skp2 controls cellular migration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom